Loading
institutionsInstitution
Asan Medical Center
Asan Medical Center is Korea's largest hospital and a global leader in liver transplantation and gastric cancer surgery.
Overview
Asan Medical Center in Seoul is Korea's largest hospital and ranks fourth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. It is known for the highest-volume living-donor liver transplant programme in the world, led by Sung-Gyu Lee, and for gastric cancer surgery, which makes it a natural major site for hepatocellular carcinoma, biliary tract and gastric cancer trials. OnCo links it to liver transplantation for cancer within and beyond the Milan criteria, to the Korean Cancer Study Group, and to oncologists including Min-Hee Ryu and Dae Ho Lee. Whether its transplant outcomes can be reproduced by lower-volume centres is the question its data invite. Its liver and gastric programmes are the reason to read this page.
Location
Seoul, KR
Type
hospital
Website
Newsweek 2026 oncology rank
#4
OnCo score
#34 · 70 points (56 Newsweek + 0 NCI + 14 from 7 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Asan Medical Center, including child institutions. 1,177 works · 18,820 citations · 72% open access · 12% clinical trials · 2% reviews.
Oncology works per year
2762022
2712023
2512024
2202025
1592026
Most works
- Dae Wook Hwang62 works
- Ki Byung Song54 works
- In Ja Park46 works
- Changhoon Yoo45 works
- Song Cheol Kim44 works
- Sung‐Bae Kim43 works
- Woohyung Lee40 works
- Tae Won Kim38 works
- Kyung Hae Jung35 works
- Yong Sang Hong34 works
Most cited
- Liver cancer and transplant
- Gastric cancer surgery
Dae Ho Lee
Professor of Medical Oncology; thoracic oncology
Lung cancerEGFR and ALK inhibitorsClinical trials
Dae Ho Lee is a thoracic oncologist behind Korean participation in the EGFR, ALK, and MET inhibitor trials that shaped lung cancer care.
Jae Lyun Lee
Professor of Medical Oncology; genitourinary cancers
Prostate cancerRenal cell carcinomaUrothelial cancer
Jae Lyun Lee is a genitourinary oncologist who brought Korean cohorts into the enfortumab, pembrolizumab, and PARP-inhibitor GU trials.
Min-Hee Ryu
Professor of Medical Oncology; gastric cancer and GIST
Gastric cancerGISTClinical trials
Min-Hee Ryu is a gastric cancer and GIST trialist central to the Asian arms of ramucirumab, pembrolizumab, and zolbetuximab studies.
Sung-Bae Kim
Professor of Medical Oncology; breast cancer
Breast cancerHER2-positive diseaseTriple-negative breast cancer
Sung-Bae Kim is a leading Korean breast oncologist on the steering committees of the trastuzumab emtansine and deruxtecan trials.
Sung-Gyu Lee
Professor of Surgery; Asan liver transplantation programme
Living-donor liver transplantationHepatocellular carcinoma surgeryHepatobiliary surgery
Built the world's highest-volume living-donor liver transplant programme, a cornerstone of liver cancer care in Asia.
Tae Won Kim
Professor of Medical Oncology; colorectal cancer
Colorectal cancerTargeted therapyClinical trials
Tae Won Kim is Korea's leading colorectal cancer trialist, an investigator on the fruquintinib, trifluridine/tipiracil, and anti-EGFR studies used worldwide.
Yoon-Koo Kang
Professor of Medical Oncology; gastric cancer and GIST
Gastric cancerGastrointestinal stromal tumourImmunotherapy
Led the ATTRACTION-2 nivolumab trial and the SPOTLIGHT zolbetuximab trial, two of the defining gastric cancer studies of the decade.
Similar pages
- TrialSPOTLIGHT & GLOW
Shares Min-Hee Ryu, Yoon-Koo Kang, Gastric & gastro-oesophageal junction cancer.
- TrialATTRACTION-2
Shares Yoon-Koo Kang, Gastric & gastro-oesophageal junction cancer.
- TermChild-Pugh and ALBI liver-function scores
Shares Liver transplantation for cancer (Milan criteria and beyond), Hepatocellular carcinoma.
- TrialRAINBOW
Shares Min-Hee Ryu, Gastric & gastro-oesophageal junction cancer.
- TreatmentZolbetuximab
Shares Min-Hee Ryu, Yoon-Koo Kang, Gastric & gastro-oesophageal junction cancer.
- InstitutionSeoul National University Hospital
Shares Korean Cancer Study Group, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer.
- Key paperLiposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
- PersonGhassan K. Abou-Alfa
Shares NIFTY, Biliary tract cancer (cholangiocarcinoma), Hepatocellular carcinoma.